Complement C5a Receptors in Hidradenitis Suppurativa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04251663|
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 5, 2020
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Examine the Roles of Complement C5a Receptors in Hidradenitis Suppurativa by ex Vivo Studies|
|Actual Study Start Date :||July 18, 2019|
|Estimated Primary Completion Date :||January 20, 2021|
|Estimated Study Completion Date :||July 20, 2021|
Subjects with active HS disease, among which at least 5 will be treatment-naïve
- CD11b surface expression on neutrophils [ Time Frame: Day 1 study visit (up to 2 hours) ]Relative expression of adhesion molecule (CD11b) on circulating neutrophils in HS patients determined by flow cytometry.
- C5aR surface expression on neutrophils [ Time Frame: Day 1 study visit (up to 2 hours) ]Relative expression of canonical complement 5a receptor (C5aR) on circulating neutrophils in HS patients determined by flow cytometry.
- Immune cell population profiling [ Time Frame: Day 1 study visit (up to 2 hours) ]Immune cell population profile as measured by the percentage of circulating neutrophils, macrophage and T cells as determined by flow cytometry.
- Measurement of cytokines [ Time Frame: Day 1 study visit (up to 2 hours) ]Skin biopsies will be cultured ex vivo. Cytokine profile as measured by the level of cytokines in assay supernatant by multiplex ELISA: IL-1β, IL-6, TNF-α, IL-12, IL-23, IL-17A, IL-17F, IFN-γ.
- Complement factor analysis [ Time Frame: Day 1 study visit (up to 2 hours) ]Complement factor (such as C1q, C4d, Bb, iC3b, C5b-9) will be analyzed by immunohistochemistry on biopsy samples (pending extra tissue availability after flow cytometry analysis)..
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04251663
|Contact: Clinical Trial Coordinatorfirstname.lastname@example.org|
|United States, California|
|Redwood City, California, United States, 94063|
|Contact: Clinical Trial Coordinator 650-721-7149 email@example.com|
|Sub-Investigator: Aatman Shah|
|Principal Investigator:||Kavita Y Sarin, MD PhD||Stanford University|